807 / 2063
ESTRO
2017
Martin et al., 2010
Hypofractionation in NSCLC
ESTRO
2017
• Benefit of hyper- and accelerated fractionation for loco-
regional control probability
• Slight increase in acute toxicity but no change in late toxicity
• Moderately hypofractionation for tumors with low
a/b
• Extreme hypofractionation for well selected indications, e.g.
small peripheral lung tumors (dose distribution effect only!)
Conclusions